AvenuesAI Regulatory Approval

Other Announcement

AvenuesAI Other Announcement

AvenuesAI Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.

Stock Split

AvenuesAI Stock Split

AvenuesAI Ltd has fixed October 13, 2026, as the record date for consolidating 10 equity shares of Re. 1 into 1 share of Rs. 10.

Annual General Meeting

AvenuesAI Annual General Meeting

AvenuesAI Limited conducted its 16th AGM on September 29, 2026, transacting eight resolutions. Key approvals included financial statements, director re-appointments, remuneration revisions, and share consolidation.

Capital Structure Change

AvenuesAI Capital Structure Change

Designated person Rahul Hirve sold 100,000 equity shares of AvenuesAI Ltd for ₹0.16 Crore in the open market.

Value

₹0.16 Cr

Capital Structure Change

AvenuesAI Capital Structure Change

Rahul Hirve, a designated person at AvenuesAI Ltd, sold 247,135 shares worth ₹0.38 Crore via market sale.

Value

₹0.38 Cr

Other Announcement

AvenuesAI Other Announcement

Designated person Rahul Hirve sold 2,47,135 equity shares of AvenuesAI Ltd worth Rs. 0.38 Crore via a market sale. This is a standard insider trading disclosure.

Value

₹0.38 Cr

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.